Niraparib plus Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

被引：0
|
作者：
Ramalingam, S. [1 ]
Arora, S. [2 ]
Neibauer, M. Whipple [2 ]
Zhou, J. [2 ]
Hazard, S. [3 ]
Frenkl, T. [2 ]
Stojadinovic, A. [2 ]
Peters, S. [4 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Glaxosmithkline, Philadelphia, PA USA
[3] Glaxosmithkline, Waltham, MA USA
[4] Lausanne Univ, Oncol, Lausanne, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
NSCLC; PARP inhibitor; niraparib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P83.02
引用
收藏
页码：S653 / S654
页数：2
相关论文
共 50 条
  • [21] KEYNOTE-522: Phase III study of pembrolizumab (pembro) 1 chemotherapy (chemo) vs placebo 1 chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)
    Schmid, P.
    Cortes Castan, J.
    Bergh, J.
    Pusztai, L.
    Denkert, C.
    Verma, S.
    McArthur, H. L.
    Zhao, J.
    Aktan, G.
    Dang, T.
    Dent, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Long-term real- world outcomes of first-line (1L) pembrolizumab (pembro) monotherapy in PD-L1 ≥50% metastatic NSCLC.
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Piperdi, Bilal
    Yang, Lingfeng
    Burke, Thomas A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L) 1 Therapy
    Hellmann, M.
    Janne, P.
    Opyrchal, M.
    Hafez, N.
    Raez, L.
    Gabrilovich, D.
    Wang, F.
    Ordentlich, P.
    Brouwer, S.
    Sankoh, S.
    Schmidt, E.
    Meyers, M.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S330 - S330
  • [24] KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
    Daud, Adil
    Blank, Christian U.
    Robert, Caroline
    Puzanov, Igor
    Richtig, Erika
    Margolin, Kim Allyson
    O'Day, Steven
    Nyakas, Marta
    Lutzky, Jose
    Tarhini, Ahmad A.
    McWhirter, Elaine
    Caglevic, Christian
    Mohr, Peter
    Millward, Michael
    Butler, Marcus O.
    Zhou, Honghong
    Emancipator, Kenneth
    Ebbinghaus, Scot
    Ibrahim, Nageatte
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors
    Perets, Ruth
    Gutierrez, Martin
    Rha, Sun Young
    Taylor, Sarah
    Stein, Brian
    Jimeno, Antonio
    Winer, Ira
    Chen, Diana
    Keenan, Tanya
    Rajasagi, Mohini
    Lala, Mallika
    Healy, Jane
    Shapira-Frommer, Ronnie
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)
    Hochmair, Maximilian
    Schenker, Michael
    Dols, Manuel Cobo
    Kim, Tae Min
    Kim, Sang-We
    Ozyilkan, Ozgur
    Smagina, Maria
    Viktoriya, Leonova
    Kato, Terufumi
    Fedenko, Alexander
    De Angelis, Flavia
    Rittmeyer, Achim
    Gray, Jhanelle E.
    Greystoke, Alastair
    Huang, Qinlei
    Zhao, Bin
    Lara-Guerra, Humberto
    Nadal, Ernest
    CANCER RESEARCH, 2024, 84 (07)
  • [27] Response to firstline (1L) pembrolizumab (pembro) plus chemotherapy (chemo) in nonsmall cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial
    Bar, Jair
    Esteban, Emilio
    Rodriguez-Abreu, Delvys
    Aix, Santiago Ponce
    Szalai, Zsuzsanna
    Felip, Enriqueta
    Gottfried, Maya
    Pulla, Mariano Provencio
    Robinson, Andrew
    Fulop, Andrea
    Rao, Suman B.
    Camidge, D. Ross
    Speranza, Giovanna
    Townson, Steven M.
    Kobie, Julie
    Ayers, Mark
    Dettman, Elisha J.
    McDaniel, Robert
    Jung, Byoungsok
    Burkhardt, David
    Mauntz, Ruth
    Csoszi, Tibor
    CANCER RESEARCH, 2023, 83 (08)
  • [28] Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%
    Lopes, G.
    Wu, Y.
    Kudaba, I.
    Kowalski, D.
    Cho, B.
    Turna, H.
    De Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K.
    Bondarenko, I.
    Kubota, K.
    Lubiniecki, G.
    Zhang, J.
    Kush, D.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S152 - S152
  • [29] Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
    Mok, T. S. K.
    Wu, Y-L.
    Kudaba, I.
    Kowalski, D. M.
    Cho, B. C.
    Turna, H. Z.
    de Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K. K.
    Bondarenko, I.
    Kubota, K.
    Caglevic, C.
    Karaszewska, B.
    Dang, T.
    Yin, L.
    Penrod, J.
    Lopes, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [30] A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED UROTHELIAL CANCER
    Gupta, Shilpa
    O'Donnell, Peter
    Plimack, Elizabeth R.
    Berger, Ranaan
    Montgomery, Bruce
    Heath, Karl
    Dolled-Filhart, Marisa
    Pathiraja, Kumudu
    Gause, Christine K.
    Cheng, Jonathan
    Perini, Rodolfo
    Bellmunt, Joaquim
    JOURNAL OF UROLOGY, 2015, 193 (04): : E861 - E862
12345